The R-Pharm Group has launched a platform for the creation of innovative therapeutic antibodies at the Laboratory for the Early Development of Biological Drugs in Pushchino, Moscow region. According to the press service of the Ministry of Investment, Industry and Science of the Moscow Region, the first molecules produced with the platform are already being tested on animals and donor cells. The Russian pharmaceutical company plans to launch pilot preclinical trials for at least 3 new molecules for the treatment of cancer and autoimmune diseases by the end of 2025.
“A dozen of projects are currently underway at the R-Pharm Research Center in Pushchino, the Laboratory for the Early Development of Biological Drugs. They are at different stages of development and cover key molecular tools of modern biomedicine,” said Ekaterina Zinovieva, Deputy Prime Minister and Minister of Investment, Industry and Science of the Moscow Region.
According to her, the Laboratory’s facilities make it possible to collect up to 200 different variants of genetic constructs annually, obtain and analyze more than 50 molecules of various structures, and deliver up to 250 cellular tests to monitor biological activity.
The laboratory at the Institute of Biological Instrumentation of the Russian Academy of Sciences has become a key element in R-Pharm’s strategy for the production of original biopharmaceuticals. The developments are carried out in close cooperation with research institutes, including specialized laboratories of the Russian Academy of Sciences. The products that are being developed by R-Pharm are intended not only for the domestic market. They already attract interest from BRICS, Southeast Asia and the Middle East countries.
The laboratory is also in the final stages of setting up the mRNA technology platform. Its implementation will expand opportunities for prevention and treatment of diseases. The specialists are now working on testing protocols for the resulting prototypes to confirm their efficacy and safety.
Earlier it was reported that the R-Pharm Group and the Siberian State Medical University signed a partnership agreement for joint research and technology development. Their activity will provide the industry with important high-tech medicines and biotechnology products.
